婦人科の出血を抗凝固剤で管理する: 血液疾患の女性と少女のための財団の推薦ツールキット
Bethany Samuelson Bannow1, Maureen Baldwin2, Madhvi Raipurkar3
1The Hemostasis & Thrombosis Center, Oregon Health & Science University; The Knight Cancer Institute, Oregon Health & Science University.
Journal of thrombosis and haemostasis : JTH
|August 31, 2025
まとめ
月経中の女性における 抗凝固剤の管理には チームワークが必要です 協力的なクリニックは 血液疾患の女性や少女のケアを改善し, 総合的な支援のために様々な専門医を巻き込みます.
科学分野:
- 血液学
- 婦人科
- 青春期 医学
背景:
- 月経中の女性における 抗凝固剤の管理は 独特の課題を提示します
- 患者さんを最適にケアするには 分野間の協力が不可欠です
- 専門の診療所が生まれています
研究 の 目的:
- 抗凝固薬による月経患者への共同治療モデルについて説明します.
- これらの診療所の医療従事者の役割を強調する.
- 複合的な出血障害の管理における学際的なチームの重要性を強調する.
主な方法:
- コラボレーションクリニックの構造と機能の見直し
- ヘマトロジスト,婦人科医,青少年医療提供者,看護師の貢献の説明
- 総合的・学際的なアプローチに重点を置く
主要な成果:
- コラボレーションクリニックは 抗凝固剤を服用している月経中の女性に 総合的なケアを提供しています
- 様々な専門家の役割が定義され,総合的な管理が保証されます.
- 血液疾患の女性と少女のための財団は,卓越したセンターを促進します.
結論:
- 月経中の女性における 抗凝固剤の有効な管理には 分野間の協力が不可欠です
- 専門のセンターは,総合的かつ協調的なケアのための枠組みを提供します.
- このモデルは 血液疾患を患っている女性や少女の 福祉を向上させます
関連する概念動画
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Esophageal Varices-II: Clinical Features and Management
135
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
135
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K


